MedTrace Logo

A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.

NCT07546214 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 575

Last updated 2026-04-22

No results posted yet for this study

Summary

To demonstrate therapeutic equivalence and safety of Tapinarof Cream, 1% (Sun pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the treatment of plaque psoriasis.

Conditions

Interventions

DRUG

Tapinarof Cream, 1%

The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.

DRUG

Vtama® (Tapinarof) Cream, 1%

The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.

DRUG

Placebo Control

The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.

Sponsors & Collaborators

  • Sun Pharmaceutical Industries, Inc.

    lead INDUSTRY

Principal Investigators

  • Natalie Yantovskiy · Sun Pharmaceuticals Industries, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-13
Primary Completion
2026-03-18
Completion
2026-03-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07546214 on ClinicalTrials.gov